Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001999371-25-006952·Affinity Asset Advisors, LLC
Schedule 13G ownership disclosure
INOZYME PHARMA INC
Common Stock, par value $0.0001 per share · CUSIP: 45790W108
Event date: 2025-05-20
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Affinity Healthcare Fund, LP
Shares: 1,867,710.00 · Class: 2.89%
- Affinity Asset Advisors, LLC
Shares: 1,867,710.00 · Class: 2.89%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001999371-25-006952
- Form type
- SCHEDULE 13G/A
- Filer
- Affinity Asset Advisors, LLC
- CIK
- CIK 1773195
- Filed
- May 30, 2025
- Reporting period
- May 20, 2025
- Description
- Schedule 13G beneficial ownership